Compare Nomura Holdings Inc (NMR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nomura Holdings Inc trades at $9.61 (market cap $27.55B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Nomura Holdings Inc is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and Nomura Holdings Inc pays a 3.4% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NMR | XBI | |
|---|---|---|
Market Cap | $27.55B | $10.11B |
Volume | 782,470 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $10.86 | $169.55 |
52-Week Low | $6.73 | $104.99 |
Typical Hold Time | 55 Days | 38 Days |
Enterprise Value | $38.54T | — |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.57, showing modest daily gains of 0.42%. The stock presents a mixed technical picture with bearish moving averages but oversold RSI readings. Fundamentally, NMR demonstrates strong profitability with 20.4% net margins and attractive valuation metrics including a P/E of 11.33 and P/B of 1.15. Recent earnings show volatility with two misses and one beat in the last four quarters. The company maintains robust revenue growth, reaching $1.66 trillion in 2025 with expanding profit margins.
NMR offers value investment appeal with reasonable valuations and solid profitability, though technical weakness and inconsistent earnings performance present near-term challenges. The stock's current oversold condition combined with strong fundamental metrics suggests potential for recovery, but investors should monitor earnings consistency and debt levels that have been trending upward. Analyst sentiment remains cautiously optimistic with a buy rating consensus despite recent technical pressure.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
